Mohamed Radwan is a Respiratory physician affiliated with University of Florida. OpenAlex indexes 98 publications with 1,317 citations (h-index 22); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1325 San Marco Blvd
Reid Building, Ste 300
Jacksonville, FL 322078568
Telephone
904-253-6910Registry record last updated 11 Apr 2017.
Clinical trials
- Effect of Colchicine On Left Ventricle Function After Anterior Myocardial Infarction Assessed By Speckle Tracking
Sponsor: Ain Shams University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Grifols USA, LLCProgram year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Abbott LaboratoriesProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
74%Corticosteroid36.5%Trelegy Ellipta85%Fluticasone Propionate Hfa15%Part D<11 patientsbeta2-Adrenergic Agonist24.7%Albuterol Sulfate Hfa100%Part D≥28 patients+ 2 more classes in this area
Metabolism & gastrointestinal
13.5%Proton pump inhibitor6.9%Omeprazole100%Part D<11 patientsCorticosteroid6.6%Prednisone100%Part D≥15 patientsAnti-infectives
8.7%Macrolide Antimicrobial8.7%Azithromycin100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Beyond Psychotropic: Potential Repurposing of Fluoxetine toward Cancer Therapy
International Journal of Molecular Sciences
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Dekosky, MD
University of Florida
Brian Hoh, MD
University of Florida
Frederic Kaye, MD
University of Florida
Kelly Foote, MD
University of Florida
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”